Lab-based COVID-19 antibody test service launch

RNS Number : 8355M

Omega Diagnostics Group PLC

26 January 2021

 

OMEGA DIAGNOSTICS GROUP PLC

("Omega" or the "Company" or the "Group")

Launch of COVID-19 antibody laboratory-based testing service

Omega (AIM: ODX), the medical diagnostics company focused on CD4, infectious diseases and food intolerance, announces that it has launched the Mologic ELISA¹ antibody test for COVID-19 through its in-house testing laboratory service in Littleport, Cambridgeshire .

This follows the successful CE marking of the capillary blood sample collection pack which is sent to healthcare professionals who then send the patient's sample back to the Company's laboratory, where the test is then run. Test results are then sent back to each healthcare professional who informs the patient of their result and provides advice as necessary.

The Company expects to offer this testing service to selected commercial occupational health partners, clinics and health care professionals in the UK.

Colin King, CEO of Omega commented: "We are pleased that we have delivered on our committed timeline for the launch of the lab testing service. This highlights our ability to react to changing market needs and utilises the skills and expertise of our long-established service Laboratory."

¹ ELISA (Enzyme Linked Immuno-Sorbent Assay) tests are one of the most tested and proven laboratory technologies used by the global diagnostic industry and remain the principal reference point from which rapid diagnostics are coordinated, especially serological tests, including tests for COVID-19.

Contacts: 

Omega Diagnostics Group PLC	Tel: [phone]
Bill Rhodes, Interim Non-Executive Chairman Colin King, Chief Executive	www.omegadiagnostics.com
Kieron Harbinson, Group Finance Director
finnCap Ltd	Tel: [phone]
Geoff Nash/Edward Whiley (Corporate Finance)
Alice Lane (ECM)
Walbrook PR Limited	Tel: [phone] or [e-mail]
Paul McManus	Mob: [phone]
Lianne Cawthorne	Mob: [phone]

 

END

 

 

NRAPPUMWGUPGPUA